Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1984-7-9
pubmed:abstractText
The pharmacokinetics of (+)-, (-)-, and (+/-)-verapamil were studied in five healthy volunteers following i.v. administration of the drugs. Pronounced differences of the various pharmacokinetic parameters were observed between the (-)- and (+)-isomers. The values for CL, V, Vz, and Vss of the (-)-isomer were substantially higher as compared to the (+)-isomer, whereas terminal t 1/ 2Z was nearly identical for both isomers. No dose dependency of the pharmacokinetics could be observed in two subjects who received 5, 7.5 and 10 mg of (-)- and 5, 25 and 50 mg of (+)-verapamil. Protein binding for the two isomers was also different. The fu of (-)- (0.11) was almost twice as much as that of (+)-verapamil (0.064). Pharmacokinetic parameters of (+/-)-verapamil, which was administered to three subjects who had received (+)- and (-)-verapamil, were very similar to the averaged values of the isomers given separately. Due to the higher CL of (-)-verapamil the extraction ratio of the (-)-isomer is substantially higher. Thus, it can be anticipated that following oral administration of racemic verapamil bioavailability of (-)-verapamil will be substantially less. Since the (-)-isomer is more potent than the (+)-isomer, the present findings could explain the reported differences in the concentration-effect relationship after i.v. and oral administration of racemic verapamil.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/6721991-1003329, http://linkedlifedata.com/resource/pubmed/commentcorrection/6721991-1004639, http://linkedlifedata.com/resource/pubmed/commentcorrection/6721991-503249, http://linkedlifedata.com/resource/pubmed/commentcorrection/6721991-529022, http://linkedlifedata.com/resource/pubmed/commentcorrection/6721991-576822, http://linkedlifedata.com/resource/pubmed/commentcorrection/6721991-7060323, http://linkedlifedata.com/resource/pubmed/commentcorrection/6721991-7128672, http://linkedlifedata.com/resource/pubmed/commentcorrection/6721991-7140136, http://linkedlifedata.com/resource/pubmed/commentcorrection/6721991-7202472, http://linkedlifedata.com/resource/pubmed/commentcorrection/6721991-7202473, http://linkedlifedata.com/resource/pubmed/commentcorrection/6721991-7206587, http://linkedlifedata.com/resource/pubmed/commentcorrection/6721991-7237897, http://linkedlifedata.com/resource/pubmed/commentcorrection/6721991-7237898, http://linkedlifedata.com/resource/pubmed/commentcorrection/6721991-7248141, http://linkedlifedata.com/resource/pubmed/commentcorrection/6721991-7295469, http://linkedlifedata.com/resource/pubmed/commentcorrection/6721991-7297023, http://linkedlifedata.com/resource/pubmed/commentcorrection/6721991-7373863, http://linkedlifedata.com/resource/pubmed/commentcorrection/6721991-7437267, http://linkedlifedata.com/resource/pubmed/commentcorrection/6721991-7460471, http://linkedlifedata.com/resource/pubmed/commentcorrection/6721991-971476
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0306-5251
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
453-8
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1984
pubmed:articleTitle
Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't